GlobeNewswire Inc | Oct 14, 2020 08:00AM EDT

October 14, 2020

WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the company will have multiple data presentations at the virtual ID Week, being held October 21-25, 2020.

The details of the poster presentations include:

?Sulbactam-durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical Isolates from the Middle East?Session Title: Novel AgentsPoster Number: 1293Presenting Author: Alita Miller, Head of Bioscience, Entasis TherapeuticsDate: Wednesday, October 21^st ?In Vitro Activity of Sulbactam-Durlobactam (ETX2514) Against Recent GlobalClinical Acinetobacter baumannii-calcoaceticus Complex Isolates?Session Title: Novel AgentsPoster Number: 1254Presenting Author: Alita Miller, Head of Bioscience, Entasis TherapeuticsDate: Wednesday, October 21^st ?Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex ? A Retrospective Review?Session Title: Respiratory Infections ? BacterialPoster Number: 1490Presenting Author: Khurram Rana, Director, Clinical Scientist, Entasis TherapeuticsDate: Wednesday, October 21^st ?A Novel ?-lactamase Inhibitor (Durlobactam, DUR) and ?-Lactams EnhanceSusceptibility Against Multidrug-Resistant (MDR) Mycobacterium abscessus (Mab)?Session Title: Tuberculosis and other Mycobacterial InfectionsPoster Number: 1642Presenting Author: Khalid M. Dousa, Fellow, Case Western Reserve UniversityDate: Wednesday, October 21^st

All poster abstract presentations will be presented on-demand Wednesday, October 21, 2020.

About Entasis

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.

Entasis Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Entasis expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, changes in the regulatory environment, failure of Entasis collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Many of these factors are beyond Entasis control. These and other risks and uncertainties are described more fully in the Entasis filings with the U.S. Securities and Exchange Commission, including the section titled Risk Factors contained therein. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Entasis Company ContactKyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com

Investor Relations ContactJames SaliernoThe Ruth Group(646) 536-7028jsalierno@theruthgroup.com

Media ContactKirsten ThomasThe Ruth Group(508) 280-6592kthomas@theruthgroup.com